How EU funds have benefited research into PCa and future plans for FP9 Jan-Willem Van de Loo, DG Research and Innovation (EC)

1. EU-funded research on
prostate cancer: towards
personalised medicine
Jan-Willem van de Loo, PhD
Scientific and Policy Officer in charge of cancer
Directorate E – Health Research
DG Research and Innovation
European Commission
EPAD, 27/09/2017

2. Research and
Innovation
Health research H2020 – what we do
• Fund international collaborative health research with EU-added value
• Initiate and support EU health policies

4. Research and
Innovation
3 Os:
• Open Innovation
• Open Science
• Open to the World
Carlos Moedas, EU
Commissioner for
Research, Science and
Innovation

5. Better health and care,
economic growth and
sustainable health
systems
Personalised medicine –
innovative healthcare
industry – global health –
sustainable and evidence–
based health-and-care
systems
Decoding the role of
the overall
environment for
health and well-being
Human exposome –
global changes and
health
Digital
transformation in
Health and Care
eHealth and mHealth
– ICT for Active and
Healthy Ageing
Trusted Big
Data solutions
and
Cybersecurity
for Health and
Care
Health, demographic change
and wellbeing challenge
for 2018-2020
Call 2018-2019-
2020:
1.8 B EUR

6. Collaborative
projectsPublic-private
partnership with
big pharma
Public-public
partnerships with
EU Member States
& beyond
Blue sky research,
training
Grants for small
businesses
Loans for small and
big R&I companies
Knowledge triangle:
Higher education,
business, R&I
Different programmes serving different
communities & purposes
EU cancer research –
where in H2020?

7. Prevention Aetiology
Diagnosis
/ Prognosis
Therapy
Model
Systems
Survivorship
/ QoL
Screening
Stratification
high-risk groups
Molecular
understanding of
disease
Molecular
classification of
cancer subtypes
Risk factors
Biomarker
identification for:
• Diagnosis
• Prognosis
• Prediction
• Monitoring
Eg: blood, urine,
saliva, tissue, tumour,
imaging
Targeted drugs via
biology-driven
hypothesis
bio-informatics to
guide treatments
Novel clinical trial
design
Wide range of
animal models
In silico models
In vitro & ex-vivo
models
('xenopatients')
Solutions for side
effects
Quality-of-life:
• Debilitation
• Infertility
• Fatigue
• Early death
• Second cancers
Prostate cancer
cohorts, screening
Biology, risk
factors, SNPs
Modelling
prognosis,
prediction
Image-guided radio
and immunotherapy
Identify radiosensi-
tive breast, prostate,
lung cancer patients
Biomarkers, big data
modelling,
ultrasound
Prostate cancer research: towards personalised medicine

8. • Linking 28 national/regional funding organisations
in 20 countries working on translational cancer
research (NO, TR, IL, TW, charities)
• TRANSCAN and TRANSCAN-2 have mobilised EUR
56 million.
Coordination of national research policies
- Stronger together
1st joint call on 'Tumour heterogeneity' (17.4 million
EUR)
2nd joint call on 'Immunotherapy' (8.9 million EUR)
3rd joint call on ' Early detection and/or progression'
(16.3 million EUR)

9. *http://cordis.europa.eu/projects/home_en.html
Biomarkers
informing care
Cancer
indication
Project Beneficiary EU
funding
What it will deliver
prostate cancer BioGuidePcA MOSAIQUES
DIAGNOSTICS GmbH
€ 50.000 diagnostic test prostate cancer for
active surveillance
prostate cancer PCSP CANVAX € 50.000 Olfactory-receptor and volatile
organic compounds in urine based
diagnostic
Prostate cancer ProCanEx PT THERAGNOSTIC BV € 50.000 Diagnostic kit based on protein
kinase activity profiling in
exosomes
prostate cancer OcProDX Otturos € 50.000 multiplexed protein diagnostic
blood test for Organ-Confined
Prostate cancer: OCProDx
Glioma GLIOMARK CONSULTECH € 4.7 million Validation of blood-brain-barrier
permeability of a 99mTc-
tetrofosmin biomarker using
SPECT-CT
Pancreatic cancer IMMPACT Immunovia AB € 4.2 million Clinical validation serum protein
biomarker for early diagnosis

10. Innovative Medicines Initiative
private partnership between the EU and pharmaceutical industry launched in• Public-private partnership between the EU and pharmaceutical industry launched in
2008
• Cancer is strategic priority (Strategic Research Agenda 2014-2020)
• Cancer research has benefited from IMI support:
IMI2 topic open
'How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer'
Imaging biomarkers -omics;
xenopatients In vitro models
Circulating tumour cell
based biomarkers
Prostate cancer

11. Part of the Investment plan for Europe, underpinning EC President Jean
Claude Juncker's agenda for Jobs, Growth, Fairness and Democratic Change
Goal
To overcome the current investment gap in the EU by mobilising private financing for strategic
investments (~€ 315 billion).
How
Via Europe's leadership on health issues contributing to effective use of public finance and mobilising
the private sector
Via economically viable projects
€ 16 billion EU budget + € 5 billion European Investment Bank (EIB) capital
Examples
Italy, Belgium, Netherlands, Austria: proton therapy centres
Hungary: biosimilars for cancer and immunology indications
Malta: state-of-the-art Oncology Centre
Latvia: Production facility radio-isotopes (PET)
EFSI - European Fund for Strategic Investment

12. Research and
Innovation
InnovFin - support to
cancer vaccines

13. Research and
Innovation
Health - research and innovation policy

14. • Establish Europe as a global leader in PM research
• Support PM science-base via a coordinated research approach
• Support research to demonstrate benefits of PM to citizens and
healthcare systems
• Prepare for PM approaches for citizens
International Consortium for Personalised
Medicine
Implementation based on PerMed Strategic Research Agenda
ICPerMed Action Plan: 22 research, 8 support actions.
Collaboration of 30 research funders and policy makers across
the EU and beyond
WHATWHYHOW
ICPerMed

15. Keep in touch!
All about Horizon 2020: visit our website
Participant portal: all EU calls and topics
Do you look beyond your favorite topic/programme?